0 92

Cited 9 times in

Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy

 Hyesun Kim  ;  Sung Chul Lee  ;  Kye Yoon Kwon  ;  Ji Hwan Lee  ;  Hyoung Jun Koh  ;  Suk Ho Byeon  ;  Sung Soo Kim  ;  Min Kim  ;  Christopher Seungkyu Lee 
 Graefes Archive for Clinical and Experimental Ophthalmology, Vol.254(8) : 1497-1503, 2016 
Journal Title
 Graefes Archive for Clinical and Experimental Ophthalmology 
Issue Date
Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage ; Bevacizumab/administration & dosage* ; Choroid/blood supply* ; Choroid/diagnostic imaging ; Choroid Diseases/diagnosis ; Choroid Diseases/drug therapy* ; Choroid Diseases/physiopathology ; Female ; Fluorescein Angiography ; Follow-Up Studies ; Fundus Oculi ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Ranibizumab/administration & dosage* ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors* ; Visual Acuity
Anti-vascular endothelial growth factor ; Polypoidal choroidal vasculopathy ; Subfoveal choroidal thickness
PURPOSE: To investigate whether subfoveal choroidal thickness predicted treatment response to anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). METHODS: This retrospective observational case series included 66 eyes of 60 patients who were diagnosed with new-onset PCV and who were followed for a minimum of 6 months. Patients received three monthly intravitreal injections of 0.5 mg ranibizumab or 1.25 mg bevacizumab, at baseline, month 1, and month 2. ""Good responders"" were defined as those who showed complete resolution of subretinal and/or intraretinal fluid at month 3 after the loading injections, whereas ""poor responders"" were defined as those who showed persistent retinal fluid on optical coherence tomography (OCT) at month 3 after treatment. Differences in best-corrected visual acuity, indocyanine green angiography, and spectral domain-OCT findings at baseline were analyzed between the two groups. RESULTS: The mean patient age was 68.2?±?9.7 years, and the mean follow-up period was 27?±?21 months. The mean subfoveal choroidal thickness was 273?±?117 μm, and choroidal vascular hyperpermeability was observed in 35 eyes (53.0 %). Thirty-three eyes (50 %) showed good response to treatment, and a thinner subfoveal choroid at baseline significantly correlated with favorable treatment response (P?=?0.024). However, there was no significant relationship between treatment response and choroidal vascular hyperpermeability (P?=?0.999). CONCLUSIONS: The subfoveal choroid was found to be significantly thinner among patients who achieved complete resolution of macular exudation after three loading injections of anti-VEGF agents.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
Kwon, Kye Yoon(권계윤)
Kim, Min(김민) ORCID logo https://orcid.org/0000-0003-1873-6959
Kim, Sung Soo(김성수) ORCID logo https://orcid.org/0000-0002-0574-7993
Kim, Hye Sun(김혜선)
Byeon, Suk Ho(변석호) ORCID logo https://orcid.org/0000-0001-8101-0830
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
Lee, Christopher Seungkyu(이승규) ORCID logo https://orcid.org/0000-0001-5054-9470
Lee, Ji Hwan(이지환)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.